These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 28095380)
21. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. Vannucchi AM; Kiladjian JJ; Griesshammer M; Masszi T; Durrant S; Passamonti F; Harrison CN; Pane F; Zachee P; Mesa R; He S; Jones MM; Garrett W; Li J; Pirron U; Habr D; Verstovsek S N Engl J Med; 2015 Jan; 372(5):426-35. PubMed ID: 25629741 [TBL] [Abstract][Full Text] [Related]
22. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib. Bryan JC; Verstovsek S Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614 [TBL] [Abstract][Full Text] [Related]
24. Ruxolitinib: a targeted treatment option for patients with polycythemia vera. Vaddi K; Verstovsek S; Kiladjian JJ Blood Lymphat Cancer; 2016; 6():7-19. PubMed ID: 31360077 [TBL] [Abstract][Full Text] [Related]
25. Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera. Parasuraman SV; Shi N; Paranagama DC; Bonafede M J Manag Care Spec Pharm; 2018 Jan; 24(1):47-55. PubMed ID: 29290171 [TBL] [Abstract][Full Text] [Related]
26. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Tefferi A; Barbui T Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051 [TBL] [Abstract][Full Text] [Related]
27. Ruxolitinib for the treatment of patients with polycythemia vera. Kiladjian JJ; Winton EF; Talpaz M; Verstovsek S Expert Rev Hematol; 2015 Aug; 8(4):391-401. PubMed ID: 25980454 [TBL] [Abstract][Full Text] [Related]
32. The advantages and risks of ruxolitinib for the treatment of polycythemia vera. Colafigli G; Scalzulli E; Pepe S; Di Prima A; Efficace F; Martelli M; Foà R; Breccia M Expert Rev Hematol; 2020 Oct; 13(10):1067-1072. PubMed ID: 32873088 [TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available. Foltz L; Pica GM; Zerazhi H; Van Droogenbroeck J; Visanica S; Báez de la Fuente E; Leber B; de Almeida AM; Ranta D; Kiladjian JJ; Chrit L; Kandra A; Morando J; Devos T Leuk Lymphoma; 2019 Dec; 60(14):3493-3502. PubMed ID: 31359808 [TBL] [Abstract][Full Text] [Related]